Chemotherapy, radiation, and immunotherapy for first-time bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of chemotherapy (gemcitabine and cisplatin), radiation, and an immunotherapy drug called sintilimab for people with first-time intrahepatic cholangiocarcinoma. The goal is to see if this combination shrinks tumors and helps people live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with intrahepatic cholangiocarcinoma, a type of bile duct cancer inside the liver.
- You have not had any previous treatment for this cancer.
- Your liver function is good (Child-Pugh class A).
- You are between 18 and 75 years old.
- You have never had radiation therapy before.
- Your overall health is good (ECOG score 0–1), meaning you can do most daily activities.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs with chemotherapy for people with advanced bile duct cancer that cannot be removed by surgery or has spread. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs for bile duct cancer that cannot be removed by surgery: sintilimab (an immunotherapy that helps your immune system fight cancer), bevacizumab (a drug that blocks blood vessel growth to tumors), and a standard chemotherapy called AG (gemcitabine and capecitabine). The goal is to see if this combination can help shrink or control the cancer as a first treatment option.
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
This trial tests a combination of three treatments—chidamide (a new type of cancer drug), chemotherapy, and immunotherapy—for advanced intrahepatic cholangiocarcinoma (a cancer of the bile ducts inside the liver). The goal is to see if this combination can shrink tumors and help patients live longer when used as a first treatment.
This Phase 3 study tests whether toripalimab (an immunotherapy) combined with lenvatinib and chemotherapy works better than standard treatment for advanced intrahepatic cholangiocarcinoma. It aims to help people live longer and/or control the cancer more effectively.
This trial tests a combination of cryoablation (freezing tumors), lenvatinib (a targeted therapy), and QL1706 (an immunotherapy) for people with advanced intrahepatic cholangiocarcinoma (bile duct cancer) that has worsened after initial treatment. The goal is to see if this combination can help stop the cancer from growing.
Hear when a new ICC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.